Clinical Trials Logo

Chronic Heart Disease clinical trials

View clinical trials related to Chronic Heart Disease.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03773991 Completed - Clinical trials for End Stage Renal Disease

Dyspnea Assessment in Hemodialysis Patients

Start date: March 29, 2019
Phase:
Study type: Observational

Shortness of breath is very common among patients on dialysis for kidney failure; however, its causes are often not understood. This study will explore the lungs and the heart of these patients to determine the causes of shortness of breath. The amount of salt in the body tissues, which tends to accumulate in dialysis patients and can also cause shortness of breath, will also be measured. Machines that exploit magnetic resonance, ultrasound and x-rays to take images of the body interior will be employed; in addition, breathing tests, questionnaires and blood tests will also be used. 20 patients on dialysis will be recruited and have two visits: one at the beginning of the study and one year later to observe any changes in the lungs, heart and salt accumulation over time.

NCT ID: NCT03339310 Completed - Heart Failure Clinical Trials

Evaluation of the Safety and Efficacy of the 2-lead OPTIMIZER® Smart System

FIX-HF-5C2
Start date: October 23, 2017
Phase: N/A
Study type: Interventional

This is a multicenter, prospective, single-arm study of the Optimizer Smart System with 2-leads

NCT ID: NCT01032395 Completed - Diabetes Mellitus Clinical Trials

Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus

Start date: March 2010
Phase: Phase 3
Study type: Interventional

This is a phase III, randomized, controlled, open label study with two vaccine regimens. The study will assess the relative safety and immunogenicity of vaccine regimens comparing adjuvanted versus non-adjuvanted formulations of A(H1N1) inactivated influenza virus vaccine in subjects with Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus, and to compare safety and immunogenicity data with a contemporaneously enrolled control group of age-comparable, healthy subjects. Because certain individuals may be hypo-responsive to influenza vaccination, additional studies with high-risk groups are warranted in order to determine the optimal vaccine formulation and dosing schedule for prevention of novel H1N1 virus infection.